|
|
Cassava Sciences Inc (NASDAQ: SAVA) |
|
Price: $2.7900
$-0.06 
-2.105%
|
| Day's High:
| $2.85
| Week Perf:
| -13.35 %
|
| Day's Low: |
$ 2.78 |
30 Day Perf: |
-89.5 % |
| Volume (M): |
1,122 |
52 Wk High: |
$ 42.20 |
| Volume (M$): |
$ 3,132 |
52 Wk Avg: |
$22.57 |
| Open: |
$2.84 |
52 Wk Low: |
$2.76 |
|
|
| Market Capitalization (Millions $) |
134 |
| Shares
Outstanding (Millions) |
48 |
| Employees |
24 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
26 |
| Cash Flow (TTM) (Millions $) |
47 |
| Capital Exp. (TTM) (Millions $) |
0 |
Cassava Sciences Inc
Cassava Sciences Inc is a biopharmaceutical company that focuses on developing drugs for the treatment of Alzheimer's disease. The company's primary drug candidate is called PTI-125, which aims to reduce neuroinflammation and improve cognition in Alzheimer's patients. Cassava Sciences also has an extensive pipeline of other candidates targeting various aspects of the disease. The company is dedicated to advancing innovative, science-driven solutions for Alzheimer's, a debilitating neurodegenerative disease that affects millions of people worldwide.
Company Address: 6801 N. Capital of Texas Highway, Building 1; Suite 300 Austin 78731 TX
Company Phone Number: 501-2444 Stock Exchange / Ticker: NASDAQ SAVA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Mon, Nov 25 2024 12:30 PM UTC
Abstract: Despite the significant investment in research and development to find effective treatments for Alzheimer s disease, many potential therapies have often failed to meet key endpoints in late-stage clinical trials. Cassava Sciences presents a recent example with their investigational drug Simufilam. In a recent public release, the company reported that the Phase 3 ...
|
| Management Announcement
Published Thu, Sep 26 2024 10:15 PM UTC
Cassava Sciences Moves Past SEC Scrutiny Amid Promising Clinical TrialsBy | In a notable turnaround for Cassava Sciences, Inc. (Nasdaq: SAVA), the Austin-based biotechnology company specializing in Alzheimer?s disease treatment, the organization has successfully navigated the turbulent waters of a U.S. Securities and Exchange Commission (SEC) investigation. On September ...
|
| Management Announcement
Published Tue, Sep 24 2024 12:30 PM UTC
In a promising development for both the company and those affected by Alzheimer?s disease, Cassava Sciences, Inc. (Nasdaq: SAVA) announced on September 24, 2024, the successful completion of a third interim safety review of its oral treatment, simufilam, in ongoing Phase 3 clinical trials. The review, conducted by an independent Data and Safety Monitoring Board (DSMB), confi...
|
| Clinical Study
Published Tue, Jul 30 2024 12:15 PM UTC
Cassava Sciences Extends Open-Label Extension Trials in Alzheimer s Clinical Programs Abstract: In a strategic move aimed at improving the continuity of care for patients with Alzheimer s disease, Cassava Sciences, Inc. has announced an extension of its open-label extension trials for simufilam, an investigational drug being evaluated in Phase 2 and Phase 3 clinical program...
|
| Stocks on the Move
Published Sat, Jul 13 2024 2:42 PM UTC
What s Next for Cassava Sciences Amidst Growing Legal Uncertainties Cassava Sciences, a biotech company specializing in Alzheimer s treatment, finds itself in an increasingly difficult position as legal uncertainties continue to mount. The company s stock performance, data integrity, and drug trial results have all come under scrutiny, raising concerns about the future of it...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.38 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
0.97 $ |
| Cash |
3.11 $
|
| Book Value |
3.47 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.38 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
0.97 $ |
| Cash |
3.11 $
|
| Book Value |
3.47 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On August 8 2024 the Cassava Sciences Inc provided following guidance
nnCassava Sciences Inc. Provides Q2 2024 Financial Results and Operational Insightsnn
AUSTIN, Texas, August 8, 2024 ? Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology firm dedicated to developing innovative treatments for Alzheimer's disease, has announced its financial performance for the second quarter ended June 30, 2024. The company achieved a net income of $6.2 million, a significant turnaround from the net loss of $26.4 million recorded during the same quarter in 2023.
In terms of operational expenses, the company reported a net cash utilization of $37.4 million during the first half of 2024, aligning with their previously issued guidance. Looking ahead, Cassava anticipates that...
|
|
|
1.82%